Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 620 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Buprenorphine Clear all
Completed Phase 2 Interventional

Reducing Sex-Related HIV Risk Behaviors in Patients Receiving Treatment for Opioid Dependence

NCT00548275
View directory record Official record
Conditions
Opiate Dependence, HIV Infections
Interventions
Enhanced Sexual Risk Management, Standard Sexual Risk Management
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers

NCT01999114
View directory record Official record
Conditions
ECG Effects
Interventions
Buprenorphine transdermal patch, Naltrexone tablet, Placebos (for TDS and for naltrexone and for moxifloxacin), Moxifloxacin tablet
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 55 Years
Enrollment
328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 20, 2026, 8:45 AM EDT
Terminated Phase 2 Interventional Results available

Optimal Treatment of Veterans With PTSD and Comorbid OUD

NCT03605342
View directory record Official record
Conditions
Post-Traumatic Stress Disorders, Opiate Use Disorder
Interventions
Buprenorphine, Cognitive Processing Therapy (CPT), Individual Drug Counseling (IDC)
Drug · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
West Haven, Connecticut • Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 20, 2026, 8:45 AM EDT
Recruiting Phase 4 Interventional

BUprenorphine Versus Morphine for Postcesarean Analgesia (BUMP)

NCT07786012
View directory record Official record
Conditions
Cesarean Delivery
Interventions
buprenorphine, morphine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
19 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Phase 3 Interventional

Study Comparing Liquid and Tablet Buprenorphine Formulations - 5

NCT00000302
View directory record Official record
Conditions
Heroin Dependence
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2005 · Synced Oct 20, 2026, 8:45 AM EDT
Recruiting Not applicable Interventional

Electronic Cigarettes as a Harm Reduction Strategy Among People With Opioid Use Disorder on Buprenorphine

NCT07202039
View directory record Official record
Conditions
Tobacco-flavored EC, Sweet-Cooling EC, Sweet Non-cooling EC
Interventions
Brief individual counseling sessions
Behavioral
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
21 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Not applicable Interventional Results available

Surmounting Withdrawal to Initiate Fast Treatment With Naltrexone

NCT04762537
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Standard Induction Procedure (SP), Rapid Induction Procedure (RP)
Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Orlando, Florida • Rockville, Maryland • Cape Girardeau, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Not applicable Interventional Results available

Psychosocial Pain Management to Improve Opioid Use Disorder Treatment Outcomes

NCT04433975
View directory record Official record
Conditions
Opioid-use Disorder, Medication Assisted Treatment, Chronic Pain
Interventions
Psychosocial Pain Management (PPMI), Enhanced Usual Care (EUC)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Phase 2 Interventional

Buprenorphine Pharmacology Related to Addiction Treatment - 18

NCT00000236
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 17, 2005 · Synced Oct 20, 2026, 8:45 AM EDT
Recruiting Phase 2Phase 3 Interventional

Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose

NCT06316830
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 20, 2026, 8:45 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Peer Recovery Support for Opioid Use Disorder Treatment Retention

NCT07620171
View directory record Official record
Conditions
Opioid Use Disorder, Peer Recovery Supporters, Peer Recovery Coaching, Primary Care, Buprenorphine
Interventions
Peer Support
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 20, 2026, 8:45 AM EDT
Not yet recruiting Phase 1 Interventional

Buprenorphine for the Management of Pain in Children With Sickle Cell Disease

NCT07799571
View directory record Official record
Conditions
Sickle Cell Disease (SCD), Sickle Cell Disease Vaso-occlusive Crisis, Sickle Cell Anemia Crisis, Sickle Cell Anemia in Children, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Sickle Cell Hemoglobin C Disease, Pain Crisis
Interventions
Buprenorphine Buccal Film [Belbuca]
Drug
Lead sponsor
Natasha Archer
Other
Eligibility
12 Years to 22 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Phase 2 Interventional

Study of Computer-Based Treatment for Drug Dependence

NCT01315184
View directory record Official record
Conditions
Opioid-Related Disorders, Heroin Dependence
Interventions
Recovery Line Support System
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Not applicable Interventional Results available

MHealth Incentivized Adherence Plus Patient Navigation

NCT06027814
View directory record Official record
Conditions
Opioid Use Disorder, Medication Adherence, Polysubstance Drug Use (Indiscriminate Drug Use), Methamphetamine-dependence
Interventions
Patient Navigation and mHealth (PN+mHealth)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact on Opioid Use of Bundling Medication-assisted Treatment With mHealth

NCT02712034
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
MAT + A-CHESS, MAT
Behavioral · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Phase 2 Interventional Results available

Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals

NCT01262092
View directory record Official record
Conditions
Opioid Dependence, Opioid Withdrawal, Opioid Detoxification
Interventions
Buprenorphine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Phase 3 Interventional

Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts - 1

NCT00000216
View directory record Official record
Conditions
Cocaine-Related Disorders, Opioid-Related Disorders, Substance-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
Yale University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Oct 20, 2026, 8:45 AM EDT
Completed No phase listed Observational

Fetal Neurobehavioral Development in Methadone Maintained Pregnancies

NCT00067184
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Toitu 320/325
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Phase 3 Interventional

Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence

NCT00630201
View directory record Official record
Conditions
Opioid Dependence
Interventions
Probuphine (buprenorphine implant)
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
15
States / cities
Los Angeles, California • National City, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 20, 2026, 8:45 AM EDT
Terminated Phase 1 Interventional

Acute Pain Management in Patients on Opioid Replacement Therapy

NCT03933865
View directory record Official record
Conditions
Opioid-use Disorder, Pain, Acute
Interventions
HYDROmorphone Injectable Solution, Ketamine, Placebos
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of RME on Engagement in Buprenorphine Treatment

NCT05184907
View directory record Official record
Conditions
Opioid Use Disorder, Behavioral Symptoms, Psychiatric or Mood Diseases or Conditions
Interventions
Remote Motivational Enhancement (RME) Intervention Arm, Information Only
Behavioral · Other
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of Buprenorphine on Responses to Verbal Tasks

NCT01860287
View directory record Official record
Conditions
Basic Science
Interventions
Buprenorphine 0.2 MG Sublingual Tablet, Placebo, Buprenorphine 0.4 MG Sublingual Tablet
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 20, 2026, 8:45 AM EDT
Not yet recruiting Phase 4 Interventional

Examining Analgesic Synergy and Efficacy in Trauma Care

NCT07435077
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine, Oxycodone
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Phase 3 Interventional Results available

Dane County Drug Court Study for Addicted Offenders

NCT01843751
View directory record Official record
Conditions
Opioid Dependence
Interventions
buprenorphine/naloxone
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
16 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 20, 2026, 8:45 AM EDT